Stocks · Healthcare · Biotechnology
MannKind Corporation MNKD
$3.80 -3.80% Close, Oct 2, 2026 · NASDAQ · Market cap $1.21B
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.14, down 225.7% year over year.
- Operating margin narrowed to 2.0% from 22.2% a year earlier.
- Revenue over the last four quarters was $393.6M, up 30.5% from a year earlier, accelerating from 21.2% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 25%
- EPS growth (TTM, YoY)Bottom 10%
- FCF growth (TTM, YoY)Bottom 8%
- Revenue growth, 3-year CAGRTop 13%
- Revenue growth accelerationTop 13%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 31%
- Gross marginTop 36%
- Operating marginTop 39%
- Accruals (lower is better)Bottom 41%
- Net debt / EBITDA (lower is better)Bottom 7%
- Interest coverTop 43%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 40%
- Free-cash-flow yieldTop 40%
- EBITDA / enterprise valueTop 32%
- Sales / enterprise valueTop 46%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 20%
- 6-month returnTop 18%
- 1-year return vs S&P 500Bottom 22%
- Distance from 52-week highBottom 39%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 16%
- Upside to consensus price targetTop 29%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 42%
- Maximum drawdown, 3 yearsTop 49%
- Beta vs S&P 500 (lower is better)Bottom 46%
- Net debt / EBITDA (lower is better)Bottom 7%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 21.2% | 30.5% | ↑ |
| EPS growth (YoY) | -175.4% | -225.7% | ↓ |
| Gross margin | 74.9% | 75.7% | ↑ |
| Operating margin | 22.2% | 2.0% | ↓ |
| FCF margin | 9.5% | -4.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 30.5% | 21.2% | ↑ | Top 25% |
| EPS growth (TTM, YoY) | -225.7% | -175.4% | ↓ | Bottom 10% |
| Gross margin | 75.7% | 74.9% | ↑ | Top 36% |
| Operating margin | 2.0% | 22.2% | ↓ | Top 39% |
| Net margin | -11.1% | 10.9% | ↓ | — |
| Free-cash-flow margin | -4.7% | 9.5% | ↓ | — |
| Return on invested capital | 1.2% | — | Top 31% | |
| Revenue growth, 3-year CAGR | 51.8% | — | Top 13% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +28.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 9.04×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 0.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.22%
- Shareholder yield
- -0.22%
- Share count change, 1 year
- -0.7%
- Share count change, 3-year CAGR
- +5.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +1.2%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $9.00
- Target vs current price
- +136.8%
- Analysts with a rating
- 20
- Share rating Buy or Strong Buy
- 50%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -700.0% | +3.5% | -3.0% | +0.5% | — |
| May 6, 2026 | -150.0% | +24.5% | +14.7% | +17.5% | +36.7% |
| Feb 26, 2026 | -400.0% | -7.4% | -15.7% | -34.9% | -5.4% |
| Nov 5, 2025 | +200.0% | +10.6% | -4.2% | +2.0% | +9.7% |
| Aug 6, 2025 | -94.6% | -13.0% | -8.3% | +38.1% | +38.8% |
| May 8, 2025 | +33.3% | -4.5% | -5.8% | -11.3% | -19.2% |
| Feb 26, 2025 | +0.0% | -3.2% | -8.8% | -7.6% | -26.2% |
| Nov 7, 2024 | -33.3% | -0.7% | -6.5% | -9.5% | -24.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.06 | -$0.01 | -700.0% | $109.4M |
| May 6, 2026 | -$0.05 | -$0.02 | -150.0% | $90.2M |
| Feb 26, 2026 | -$0.05 | -$0.01 | -400.0% | $112.0M |
| Nov 5, 2025 | $0.03 | $0.01 | +200.0% | $82.1M |
| Aug 6, 2025 | $0.00 | $0.04 | -94.6% | $76.5M |
| May 8, 2025 | $0.04 | $0.03 | +33.3% | $78.4M |
| Feb 26, 2025 | $0.03 | $0.03 | +0.0% | $76.8M |
| Nov 7, 2024 | $0.04 | $0.06 | -33.3% | $70.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 48.5× | — | — | Top 32% |
| EV / Sales | 3.79× | — | — | Top 46% |
| Free-cash-flow yield | -1.53% | — | — | Top 40% |
| Earnings yield | -3.61% | — | — | Top 40% |
P/E over the past five years
Range 31.8× – 186.4× since Mar 31, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -29.4%
- Earnings per share growth (TTM)
- -225.7%
- Change in P/E multiple
- +174.8%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.4%
- 200-day average slope (20 days)
- -4.3%
- Distance from 50-day average
- -1.5%
- Distance from 200-day average
- -4.5%
- RSI (14)
- 53.4
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.9%
- Volatility vs own 5-year history
- 61th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.19
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -38.8%
- Maximum drawdown, 3 years
- -69.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 6, 2024 | Mar 25, 2026 | -69.3% | 344 days | Not yet recovered |
| Feb 19, 2021 | Feb 28, 2022 | -57.3% | 258 days | 629 days (Aug 29, 2024) |
| Dec 17, 2020 | Dec 31, 2020 | -22.5% | 9 days | 22 days (Feb 3, 2021) |
| Nov 27, 2020 | Dec 7, 2020 | -11.0% | 6 days | 5 days (Dec 14, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.21B
- EPS, diluted (TTM)
- -$0.14
- Revenue (TTM)
- $393.6M
- 52-week range
- $2.23 – $6.51
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $75.4M | $99.8M | $199.0M | $285.5M | $349.0M |
| Gross profit | $36.6M | $42.3M | $136.2M | $208.9M | $287.8M |
| Operating income | -$47.0M | -$64.1M | $8.7M | $72.6M | $38.8M |
| Net income | -$80.9M | -$87.4M | -$11.9M | $27.6M | $5.9M |
| EPS (diluted) | -$0.37 | -$0.44 | -$0.04 | $0.10 | $0.02 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.1M | $76.8M | $78.4M | $76.5M | $82.1M | $112.0M | $90.2M | $109.4M |
| Net income | $11.6M | $7.4M | $13.2M | $668,000 | $8.0M | -$15.9M | -$16.6M | -$19.0M |
| EPS (diluted) | $0.04 | $0.03 | $0.04 | $0.00 | $0.03 | -$0.05 | -$0.05 | -$0.06 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$61.7M | -$80.7M | $34.1M | $42.5M | $18.3M |
| Capital expenditure | -$11.5M | -$7.6M | -$42.4M | -$9.7M | -$4.6M |
| Free cash flow | -$73.2M | -$88.3M | -$8.3M | $32.8M | $13.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $1.9M | $22.6M | $6.9M | -$6.1M | -$3.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $111.1M
- Total assets
- $732.3M
- Total liabilities
- $799.5M
- Total debt
- $330.8M
- Net debt
- $277.9M
- Shareholders’ equity
- -$67.2M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 29,398,550
- Days to cover
- 9.08
- Change vs previous report
- +10.7%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Mar 3, 2017
- 1-for-5